Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567991 | 0.82 | SMN1; SMN2 (0.35) | ACACBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL12478570 | 0.77 | RXFP1 (0.41) | ALDH1A1MAPTHPGDRXFP1POLB | |
| SCHEMBL15524398 | 0.75 | MTNR1A (0.38) | ACACBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL5212760 | 0.72 | ACACB (0.50) | ACACBKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL22924834 | 0.72 | KMT2A (0.44) | KMT2AKDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL28148693 | 0.71 | L3MBTL1 (0.39) | ACACBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3623135 | 0.71 | KDM4E (0.43) | KMT2AKDM4EALDH1A1HSD17B10FFAR1 | |
| SCHEMBL15524418 | 0.69 | FFAR1 (0.47) | KDM4EALDH1A1HSD17B10FFAR1MAPT | |
| SCHEMBL6803353 | 0.68 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL14617547 | 0.68 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| EP-2885292-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| WO-2014026242-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ACACB 2987/4885KMT2A 4210/4885KDM4E 2523/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ACACB 2249/4885KMT2A 3938/4885KDM4E 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.